GDPR applied to clinical trials: in 2026, compliance in health research can no longer be treated as a mere administrative addendum. It is an integral part of protocol design, relationships with investigational centers, subcontractor management, regulatory documentation, and transparency toward participants.
With the widespread adoption of the CTIS for clinical trials of medicinal products, the increasing digitalization of studies, remote quality controls, ePRO/eConsent tools, monitoring platforms, and the rise of international multicenter studies, personal data flows more heavily, faster, and between more actors. However, clinical trials handle particularly sensitive information: health data, genetic data, biological data, identification data, data from care pathways, or data collected via digital devices.
In France, the CNIL published a major update to the MR-001 and MR-003 reference methodologies on May 26, 2026, expanding their scope and providing new clarifications on studies abroad, dematerialized information, remote quality control, transfers outside the European Union, subcontractors, and data security.
GDPR Applied to Clinical Trials: Why Compliance Must Be Anticiped Right From the Protocol
The first mistake is thinking that GDPR only comes into play when drafting the patient information sheet. In reality, GDPR applied to clinical trials must be anticipated as early as the study design phase.
The protocol must justify the data collected, their purpose, their scientific necessity, and their retention period. This logic aligns with the principle of data minimization: only data useful for the research objectives should be collected. Furthermore, the CNIL recommends completing compliance grids during the very first steps of the project to integrate applicable requirements right into the design of data processing.
In clinical trials of medicinal products, European Regulation No. 536/2014 governs authorization requests and has replaced Directive 2001/20/EC. In France, the application dossier notably includes a specific Part II, which covers recruitment methods, information, consent, compensation, insurance, and compliance with the GDPR. The ANSM reminds us that this regulation has been the applicable legal framework since January 31, 2022.
GDPR Compliance Checklist for Clinical Trials in 2026
1. Identify the Applicable Reference Methodology
Before taking any steps, it is necessary to determine whether the research falls under MR-001, MR-003, or another framework. MR-001 concerns health research requiring the collection of consent for participation in the research or for performing a specific act. MR-003, on the other hand, governs research that does not require this collection of consent to participate in the research or perform a specific act.
If the study strictly complies with the reference methodology and its appendices, a declaration of compliance may suffice. However, if any point of non-compliance exists, the data controller must submit a “research” authorization request to the CNIL, after obtaining the opinion of the competent ethics committee.
Sources: https://www.cnil.fr/fr/methodologie-de-reference-mr-001-recherches-sante-avec-recueil-du-consentement, https://www.cnil.fr/fr/methodologie-de-reference-mr-003-recherches-dans-le-domaine-de-la-sante-sans-recueil-du-consentement
2. Distinguish Consent to Research From the GDPR Legal Basis
In a clinical trial, the participant’s informed consent is an ethical and regulatory requirement. However, it must not be confused with the legal basis for processing personal data under the GDPR. The European Data Protection Board recalls that consent under the Clinical Trials Regulation does not automatically serve as the legal basis for personal data processing.
This distinction is crucial. The sponsor must therefore document the legal basis chosen for each processing operation: legal obligation, public interest task, legitimate interest, or GDPR consent in certain cases. For health data, they must also identify the applicable exception under Article 9 of the GDPR.
Source: https://health.ec.europa.eu/document/download/c3042973-b36d-4094-a1fb-a6fc980f065e_en
3. Update Participant Information
Patient information must be clear, accessible, and comprehensive. It must explain the purposes of the processing, the categories of data collected, the recipients, data subject rights, the retention period, potential transfers outside the European Union, and the DPO’s contact details.
In 2026, dematerialized information becomes a central topic. It can streamline the participant journey, but it must remain understandable, traceable, and adapted to the study’s risk level. The framework of GDPR applied to clinical trials therefore requires verifying not only the content of the information but also how it is delivered.
4. Secure Access and Digital Tools
Clinical trials increasingly rely on electronic platforms: eCRF, eConsent, ePRO, monitoring solutions, randomization tools, investigator portals, or shared databases. Each tool must be evaluated in terms of security, confidentiality, access traceability, and data localization.
The 2026 update of the reference methodologies is accompanied by dedicated appendices on security and quality control. The CNIL notably indicates that MR-001 and MR-003 aim to guarantee data security and to verify the completeness and accuracy of the collected data.
5. Oversee Subcontractors and CROs
The sponsor remains the data controller, even when delegating operations to a CRO, a data manager, a hosting provider, an eConsent vendor, or a monitoring provider. Contracts must therefore specify roles, responsibilities, documented instructions, security measures, conditions for sub-processing, audit modalities, and rules for data return or deletion.
6. Anticipate International Transfers
Multicenter trials often involve data transfers to entities located outside the European Union. In 2026, this point must be documented with precision: countries involved, recipients, safeguards put in place, standard contractual clauses, risk assessments, and participant information.
7. Prepare CTIS Transparency Without Exposing Personal Data
The CTIS is the single entry point for the submission, assessment, and supervision of clinical trials in the European Union and the European Economic Area. It also enables the publication and registration of trials in a public registry. Since June 2024, the revised transparency rules and the new CTIS public portal reinforce the importance of clearly distinguishing between publishable information, confidential information, and personal data.
Source: https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-information-day
Compliance to Document, Not Just to Declare
The effective framework of GDPR applied to clinical trials relies on a logic of accountability and proof. It is not enough to be compliant; you must be able to demonstrate it. The data processing register, data protection impact assessments (DPIA) where necessary, subcontracting agreements, MR-001 or MR-003 grids, security documentation, rights management procedures, access traceability, and archiving must all be mutually consistent.
For sponsors, CROs, investigators, and project teams, 2026 marks an important milestone. GDPR compliance is becoming a real driver for quality, trust, and regulatory robustness. Well-integrated from the very design of the trial, GDPR applied to clinical trials secures clinical development, protects participants, and reduces the risks of roadblocks during submissions, inspections, or audits.
